Friday, July 17, 2015

Top Freight Stocks To Watch Right Now

Top Freight Stocks To Watch Right Now: Werner Enterprises Inc (WERN)

Werner Enterprises, Inc., incorporated on September 14, 1982, is a transportation and logistics company engaged primarily in hauling truckload shipments of general commodities in both interstate and intrastate commerce. The Company also provides logistics services through its value added services (VAS) division. As of the year ended December 31, 2012, the Company had a fleet of 7,150 trucks, of which 6,505 were Company-operated and 645 were owned and operated by independent contractors. The Company operates in two segments: Truckload Transportation Services (Truckload) and VAS.

Truckload segment

The Company's Truckload segment consists of the One-Way Truckload and Specialized Services units. One-Way Truckload includes the operating fleets: the regional short-haul (Regional) fleet transports a variety of consumer nondurable products and other commodities in truckload quantities within geographic regions across the United States using dry van trai lers; the medium-to-long-haul van (Van) fleet provides comparable truckload van service over irregular routes, and the expedited (Expedited) fleet provides time-sensitive truckload services utilizing driver teams.

Specialized Services provides truckload services dedicated to a specific customer, generally for a retail distribution center or manufacturing facility, including services for products requiring specialized trailers such as flatbed or temperature-controlled trailers. The Company's Truckload fleets operate throughout the 48 contiguous United States, both common and contract, granted by the United States Department of Transportation (DOT). The Company also has authority to operate in several provinces of Canada and to provide through-trailer service into and out of Mexico. The principal types of freight the Company transports include retail store m! erchandise, consumer products, grocery products and manufactured products. The Company focuses on transport ing consumer nondurable products that generally ship.

!

VAS segment

The Company's VAS segment is a non-asset-based transportation and logistics provider. VAS is consists of four operating units that provide non-trucking services to the Company's customers: truck brokerage (Brokerage) uses contracted carriers to complete customer shipments; freight management (Freight Management) offers a range of single-source logistics management services and solutions; the intermodal (Intermodal) unit offers rail transportation through alliances with rail and drayage providers as an alternative to truck transportation, and Werner Global Logistics international (WGL) provides complete management of global shipments from origin to destination using a combination of air, ocean, truck and rail transportation modes. The Company's Brokerage unit had transportation services contracts with approximately 9,400 carriers as of December 31, 2012.

Advisors' Opinion:
  • [By Mike Deane]

    Werner Enterprises (WERN) announced its third quarter earnings after the bell on Thursday, posting a 1% change in revenues from last year’s Q3, but a 15% drop in net income.

    The Omaha, NE-based logistics and transportation company announced Q3 revenue of $511.73 million, which was up slightly from last year’s $506.50 million revenue figure. WERN reported net income for the quarter of $21.53 million, or 29 cents per diluted share, which was down from last year’s Q3 earnings of $25.13 million, or 34 cents per diluted share.

    The company was able to meet analyst views of 29 cents EPS, and slightly surpass the revenue estimate of $503.82 million.

    WERN shares were up 21 cents, or 0.90%, at Thursday’s market close, but were edging lower in after-hours trading. YTD, the company’s stock is up just over 4%.

  • [By Monica Gerson] !

    Werner! Enterprises (NASDAQ: WERN) is expected to post its Q3 earnings at $0.29 per share on revenue of $503.82 million.

    Chipotle Mexican Grill (NYSE: CMG) is estimated to post its Q3 earnings at $2.78 per share on revenue of $820.28 million.

  • [By Seth Jayson]

    Werner Enterprises (Nasdaq: WERN  ) reported earnings on April 18. Here are the numbers you need to know.

    The 10-second takeaway
    For the quarter ended March 31 (Q1), Werner Enterprises missed estimates on revenues and missed estimates on earnings per share.

  • [By Rich Duprey]

    Transportation and logistics specialist Werner Enterprises (NASDAQ: WERN  ) announced this morning its second-quarter dividend of $0.05 per share, the same rate it's paid since 2007.

  • source from Top Stocks For 2015:http://www.topstocksblog.com/top-freight-stocks-to-watch-right-now-5.html

Wednesday, July 15, 2015

Top Airline Stocks To Buy For 2016

Top Airline Stocks To Buy For 2016: Controladora Vuela Compania de Aviacion SAB de CV (VLRS)

Controladora Vuela Compania de Aviacion SAB de CV (Volaris Aviation Holding Company) is a Mexico-based company principally engaged in the airline passenger transportation industry. The Company is a law-cost carrier airline. Controladora Vuela Compania de Aviacion SAB de CV offers direct, point-to-point flights. The Company serves through secondary, lower cost airports and provides a single class of service. The Company utilizes such aircraft as the Airbus A319 and A320 families, among others. The Company has such subsidiaries as Comercializadora Volaris SA de CV, Servicios Corporativos Volaris SA de CV, Concesionaria Vuela Compania de Aviacion SAPI de CV, Deutsche Bank Mexico SA Trust 1484, among others. Advisors' Opinion:
  • [By John Udovich]

    When most American investors think of discount airline stocks, they probably think of relatively large capped Southwest Airlines Co (NYSE: LUV)or sort of small capJetBlue Airways Corporation (NASDAQ: JBLU) rather thansmall cap Controladora Vuela Co Avcn SA CV (NYSE: VLRS) which owns Volaris a discount airline serving theMexican market. However, any investor who has read Benjamin Grahams Intelligent Investor might want to remember his sage advice about avoiding airline stocks mainly because airlines were such a new and unproven sector that had yet to make money. But could Controladora Vuela Co Avcn SA CV actually be an airline stock worth owning?

  • source from Top Stocks To Buy For 2015:http://www.topstocksforum.com/top-airline-stocks-to-buy-for-2016.html

Thursday, July 9, 2015

Hot Transportation Stocks To Own Right Now

If you think natural gas prices could wreak havoc on companies like Clean Energy Fuels� (NASDAQ: CLNE  ) �and�Questar's� (NYSE: STR  ) refueling division, you probably don't understand how it all adds up "at the pump."

Andrew Littlefair is the CEO and co-founder of Clean Energy Fuels, the leading provider of natural gas for transportation in North America. Clean Energy provides CNG and LNG fuels to solid waste, trucking, and transit fleets, among others, and currently operates some 500 fueling stations in the United States and Canada, as well as manufacturing related equipment and technologies.

Is natural gas losing its ability to compete as a transportation fuel? In this video segment, Littlefair explains the commodity cost of natural gas, and how it really compares to diesel -- and what a change in the price of natural gas ultimately means at the pump.�

OPEC is absolutely terrified of this game-changer...
It's hard to know which companies will be winning investments in the American energy boom. One company is so tied to every aspect of production, exploration, and distribution, it literally has no competition in some of its business segments. Warren Buffett is so confident in this one company's can't-live-without-it business model, he loaded up on 8.8�million shares. An exclusive Motley Fool report reveals the company we're calling OPEC's Worst Nightmare. Just click HERE to uncover the name of this industry-leading stock. It could be one of the best stocks to own in over the next two decades.�

Best Prefered Stocks To Own For 2016: Rhino Resource Partners LP(RNO)

Rhino Resource Partners LP produces, processes, and sells coal of various steam and metallurgical grades in the United States. The company holds interests in various surface and underground coal mines located in Central Appalachia, Northern Appalachia, the Illinois Basin, and the Western Bituminous region. As of December 31, 2010, it operated 10 mines, including 5 underground and 5 surface mines located in Kentucky, Ohio, and West Virginia. The company markets its steam coal primarily to electric utility companies as fuel for their steam-powered generators; and metallurgical coal for steel and coke producers. It also engages in mining limestone from reserves located at its Sands Hill mining complex and sells it as aggregate to various construction companies and road builders. The company was founded in 2003 and is based in Lexington, Kentucky.

Advisors' Opinion:
  • [By Rich Duprey]

    Coal producer�Rhino Resource Partners� (NYSE: RNO  ) announced yesterday its third-quarter dividend of $0.445 per share, the same rate it's paid for the past four quarters after cutting the payout 7% from $0.48 per share.

  • [By Dorothee Tschampa]

    Volkswagen AG (VOW) (VOW), PSA Peugeot Citroen (UG) and Renault SA (RNO) (RNO), Europe�� three largest carmakers, all dropped 5 percent or more after preliminary data showed Chinese manufacturing is unexpectedly contracting.

  • [By Robert Rapier]

    The National Association of Publicly Traded Partnerships (NAPTP) lists five MLPs in the category ��atural Resources – Coal,��although two of the five are Alliance Holdings (NYSE: AHGP) and its operating affiliate, Alliance Resource Partners (NYSE: ARLP). The other three are Natural Resource Partners (NYSE: NRP), Rhino Resource Partners (NYSE: RNO), and Oxford Resource Partners (NYSE: OXF).

  • [By Alexis Xydias]

    Investors are regaining confidence, squeezing pessimists who say the economy remains sluggish outside of Germany and point to record-low trading volume as a lack of conviction in the Euro Stoxx�� 61 percent rally of the past two years. Besides gains in stocks from Banco Bilbao Vizcaya Argentaria SA to Renault SA (RNO), yields on Spanish and Italian bonds have declined to a two-year low compared with German bunds and the euro has strengthened 4.6 percent to $1.35 in the past six months.

Hot Transportation Stocks To Own Right Now: United Parcel Service Inc.(UPS)

United Parcel Service, Inc., a package delivery company, provides transportation, logistics, and financial services in the United States and internationally. It operates in three segments: U.S. Domestic Package, International Package, and Supply Chain & Freight. The U.S. Domestic Package segment engages in the time-definite delivery of letters, documents, and packages in the United States. The International Package segment offers air and ground delivery of small packages and letters to approximately 220 countries and territories, including shipments outside the United States, as well as shipments with either origin or distribution outside the United States; export services; and domestic services move shipments within a country?s borders. The Supply Chain & Freight segment provides forwarding and logistics services, such as supply chain design and management, freight distribution, customs brokerage, mail, and consulting services in approximately 195 countries and territorie s; and less-than-truckload and truckload services to customers in North America. In addition, the company offers various technology solutions for automated shipping, visibility, and billing; information technology systems and distribution facilities to various industries comprising healthcare, technology, and consumer/retail; and a portfolio of financial services that provides customers with short-term working capital, government guaranteed lending, global trade financing, credit cards, and export financing. It operates a fleet of approximately 99,800 package cars, vans, tractors, and motorcycles; an air fleet of 527 aircraft; and 33,800 containers used to transport cargo in its aircraft. The company was founded in 1907 and is headquartered in Atlanta, Georgia.

Advisors' Opinion:
  • [By Bloomberg]

    Associated Press/Brennan Linsley When Hostess Brands went bankrupt in 2012, it triggered anxiety among employees at Ottenberg's Bakery, a family-owned enterprise in Maryland. The companies shared a pension plan, and if Hostess couldn't pay its retirees, Ottenberg's would have to pick up the tab. Gary League, 53, who has delivered Ottenberg's bread for almost three decades, worried he might lose his nest egg, maybe even his job. "If you have all these guys out on retirement and you only have Ottenberg's paying into it, the math doesn't add up," he said. "I was thinking I would have to work forever." Last week, he got the good news -- the U.S. government saved his benefits by sacrificing those of Hostess' drivers, who will now get a reduced payout financed by the government. League is one of 10.4 million Americans with retirements tied to multiemployer pension plans, large investment pools long considered low risk because they don't rely on a single company for financing. Two recessions, industry consolidation prompted by deregulation and an aging workforce have funds facing a $400 billion shortfall that has some near insolvency. Dozens already have failed, affecting 94,000 participants. Things are dire enough that a coalition of employers and labor unions is asking Congress for permission to cut benefits to retired truck drivers, miners and others as a last resort in order to prevent plans from going under. The proposal has divided unions and their allies, triggering a lobbying battle as a legislative deadline approaches and retirement security looms large as a growing economic concern. $2 Billion LIability Leads to Plan Being Carved up Hostess, maker of Wonder Bread and Twinkies, was one of two employers contributing to the Bakery and Sales Drivers Local 33 Pension Fund. When Hostess went bankrupt, Ottenberg's was left to foot the bill. President Ray Ottenberg didn't respond to requests for comment. Hostess had about $2 billion in liability to its multi

  • [By Rich Smith]

    This series, brought to you by Yahoo! Finance, looks at which upgrades and downgrades make sense, and which ones investors should act on. Today, three new ratings in the shipping sphere are grabbing headlines, as investment banker RBC Capital Markets upgrades UPS (NYSE: UPS  ) to outperform, but cuts both FedEx (NYSE: FDX  ) and shipping facilitator Expeditors International (NASDAQ: EXPD  ) to underperform.

Hot Transportation Stocks To Own Right Now: Frontline Ltd (FRO)

Frontline Ltd., incorporated on June 12, 1992, is a shipping company. The Company is engaged primarily in the ownership and operation of oil tankers and oil/bulk/ore (OBO) carriers. The Company operates tankers of two sizes: very large crude carriers (VLCCs), which are between 200,000 and 320,000 deadweight tons, and Suezmax tankers, which are vessels between 120,000 and 170,000 deadweight tons. As of December 31, 2010, its tanker and OBO fleet consisted of 73 vessels. The fleet consists of 44 VLCCs, which are either owned or chartered in, 21 Suezmax tankers, which are either owned or chartered in and eight Suezmax OBOs, which are chartered in. The Company also had five VLCC newbuildings and two Suezmax newbuildings on order and three VLCCs under its commercial management. In February 2010, it purchased the VLCC Front Vista from Ship Finance International Limited (Ship Finance). In January 2011, it sold the VLCC Front Shanghai.

The Company operates through subsidiaries and partnerships located in the Bahamas, Bermuda, the Cayman Islands, India, the Isle of Man, Liberia, Norway, the United Kingdom and Singapore. The Company is also engaged in the charter, purchase and sale of vessels. In April 2010, the Company delivered the single hull Suezmax Front Voyager. During the year ended December 31, 2010, six newbuildings were completed. Four Suezmax vessels were delivered: the Northia, on January 5, 2010; the Naticina, on March 9, 2010; the Front Odin, on May 5, 2010, and the Front Njord on August 12, 2010. Two VLCCs were delivered: the Front Cecilie on June 10 and the Front Signe on August 9, 2010. As of December 31, 2010, the Company's newbuilding program consisted of two Suezmax tankers and five VLCCs.

Advisors' Opinion:
  • [By Karee Venema]

    One equity that falls under the small-cap umbrella, and looks poised to benefit from a contrarian boon is shipping concern Frontline Ltd. (FRO).

    Shares of Frontline have more than doubled in value since hitting a decade-plus low of $1.71 last May. In fact, the stock tagged a new annual high of $5.18 in early January.

Hot Transportation Stocks To Own Right Now: Canadian Pacific Railway Limited(CP)

Canadian Pacific Railway Limited, through its subsidiaries, operates as a transcontinental railway providing freight transportation services, logistics solutions, and supply chain expertise in Canada and the United States. It transports bulk commodities, including grain, coal, sulphur, and fertilizers; merchandise freight; finished vehicles and automotive parts; forest products, which include wood pulp, paper, paperboard, newsprint, lumber, panel, and oriented strand board; and industrial and consumer products comprising chemicals, energy, and plastics, as well as mine, metals, and aggregates. The company provides rail and intermodal transportation services over a network of approximately 14,700 miles serving the principal business centers of Canada, from Montreal to Vancouver, British Columbia; and the Midwest and Northeast regions of the United States. Canadian Pacific Railway Limited was founded in 1881 and is headquartered in Calgary, Canada.

Advisors' Opinion:
  • [By Teresa Rivas]

    Canadian Pacific Railway�(CP) wants to merge with�CSX Corp. (CSX), and shareholders seem to like the idea as well, sending both stocks up Monday.

    However, CSX isn�� sold: As The Wall Street Journal�� Dana Mattioli, Liz Hoffman and David Georg-Cosh report, it resisted CP�� offer, and there�� no guarantee the latter will try again.

    Also among the skeptics: Cowen & Co.�� Jason Seidl and Matthew Elkott. In a note out today, the write that the timing is not ideal for a mega merger: While such a deal would likely benefit both companies in the long run, ongoing service and capacity issues have soured shippers and regulators on the industry at the whole. Indeed, their recent survey showed 70% of shippers are opposed to another merger among Class 1 railroads, an increase from 64% in the second quarter. As it stands, current service issues are unlikely to ease until mid-2015, and shippers, recalling integration issues associated with previous mergers, are likely loath to see that protracted timeline stretched any further.

    So what comes next, in their opinion?

    If CP has shelved the offer, it could mean that a Class I merger may not be revisited for a while. However, given the tenacity of CP�� management, we would not be surprised if the company resorts to other means for making the deal happen. Indeed, management could team up with Pershing Square Capital in taking the proposal directly to CSX�� shareholders. While the activist fund has won many accolades from investors for its remarkable success in turning around CP over the last couple of years, a merger between the two carriers will likely still face many hurdles, not the least of which will be the Surface Transportation Board (STB), which has been listening intently to shippers��service and rail pricing concerns. Other regulatory and national security authorities will likely be involved.

    However, if a merger does happen, expect others to quickly follow, write Seid

  • [By Dan Caplinger]

    Earlier this week, CSX (NYSE: CSX  ) saw its stock soar by 10% as news emerged that North American peer Canadian Pacific (NYSE: CP  ) had reportedly approached CSX with a possible merger deal. Yet even as investors speculated about the possible implications of a merger on the short-term value of their holdings, CSX's earnings the following afternoon gave the railroad's shareholders plenty of reasons not to want to give Canadian Pacific the chance to buy them out at what could prove to have been a bargain price.

  • [By Jon C. Ogg]

    Canadian Pacific Railway Ltd. (NYSE: CP) was upgraded to Outperform from Neutral and the price target was raised to $144 from $139 at Credit Suisse.

Hot Transportation Stocks To Own Right Now: CAI International Inc (CAP)

CAI International, Inc., incorporated on January 30, 2007, is a equipment leasing and management company, operating primarily in the international intermodal marine cargo container leasing business. The Company also owns a fleet of railcars, which it leases in North America. The Company operates in two segments: equipment leasing and equipment management. The equipment leasing segment specializes primarily in the ownership and leasing of intermodal containers, while the equipment management segment manages equipment for third-party investors. The Company leases its equipment principally to international container shipping lines located throughout the world. The Company sells equipment primarily to third-party investor groups and provides management services to those investors in return for a management fee.

The equipment leasing segment derives its revenue primarily from the ownership and leasing of containers to container shipping lines and freight forwarders. The equipment management segment derives its revenue from management fees earned from portfolios of equipment and associated leases which are managed on behalf of third-party investors. As of March 31, 2013, our fleet consisted of 1,091,117 twenty-foot equivalent units (TEUs) of containers and 1,453 railcars.

Advisors' Opinion:
  • [By Sarah Jones]

    SAP AG (SAP) climbed 1.2 percent to 57.36 euros and Cap Gemini SA (CAP) gained 1.8 percent to 39.95 euros as peer Infosys Ltd. surged the most in six months in Mumbai trading after first-quarter profit rose and the company�� sales forecast in dollar terms beat analyst estimates.

Hot Transportation Stocks To Own Right Now: Saia Inc.(SAIA)

Saia, Inc., an asset-based trucking company, provides transportation and supply chain solutions primarily to the retail, chemical, and manufacturing industries in the United States. The company, through it subsidiary, Saia Motor Freight Line, LLC, offers regional and interregional less than truckload (LTL) services, selected national LTL, and time-definite services. It was formerly known as SCS Transportation, Inc. Saia, Inc. was founded in 2000 and is headquartered in Johns Creek, Georgia.

Advisors' Opinion:
  • [By Ben Levisohn]

    Wunderlich’s Nicholas Bender thinks FedEx’s results bode well for Old Dominion (ODFL), Con-way (CNW) and Saia (SAIA):

    We expect all less-than-truckload carriers to benefit in 2Q14 from the same trends that carried FedEx Freight to a banner 4Q14. This includes Hold-rated Old Dominion, which will continue to grow at well above market rates, and Buy-rated Con-way, which we believe can leverage a strong 2Q14 to prime the pump on margin enhancement efforts. Our favorite name in the space remains Saia (SAIA-$42.92, Buy), which will once again see accelerating tonnage growth in 2Q14. Though tonnage growth will moderate in� 2H14 due to steeper comps, there remains considerable potential for the company to boost yield and continue winning incremental business with new accounts.

  • [By John Udovich]

    Despite what can best be described as a�soft economy, small cap trucking stocks YRC Worldwide, Inc (NASDAQ: YRCW), Arkansas Best Corporation (NASDAQ: ABFS), Frozen Food Express Industries, Inc (NASDAQ: FFEX), Saia Inc (NASDAQ: SAIA) and USA Truck, Inc (NASDAQ: USAK) have been trucking some pretty impressive returns since the start of the year. In fact, these small cap trucking stocks are up anywhere from 72% to 150% or so since the start of the year despite the slow economy. Certainly trucking stocks provide a good indicator of how the economy is doing, but might investors be�jumping the gun by pushing up these trucking stocks?

Monday, July 6, 2015

Top 10 Asian Stocks To Watch For 2016

Top 10 Asian Stocks To Watch For 2016: Balchem Corp (BCPC)

Balchem Corporation incorporated on Jan 30, 1967, is engaged in the development, manufacture and marketing of specialty performance ingredients and products for the food, nutritional, feed, pharmaceutical and medical sterilization industries. The Company operates in three segments: Specialty Products, Food, Pharma & Nutrition and Animal Nutrition & Health. The Company sells its products through its own sales force, independent distributors and sales agents. The Company operates five wholly owned domestic subsidiaries, such as BCP Ingredients, Inc., Aberco, Inc., Balchem BV, Balchem Trading BV and Balchem Italia Srl.

Food, Pharma & Nutrition

The Food, Pharma & Nutrition (FPN) segment provides microencapsulation solutions to a variety of applications in food, pharmaceutical and nutritional ingredients to enhance performance of nutritional fortification, processing, mixing, and packaging applications and shelf-life. Major product applications are bak ed goods, refrigerated and frozen dough systems, processed meats, seasoning blends, confections, and nutritional supplements. The Company also markets human grade choline nutrient products through this segment for wellness applications.

Specialty Products

The Company's Specialty Products segment operates in industry as ARC Specialty Products. Ethylene oxide, at the 100% level, is sold as a sterilant gas, primarily for use in the health care industry. It is used to sterilize a wide range of medical devices because of its versatility and effectiveness in treating hard or soft surfaces, composites, metals, tubing and different types of plastics. The Company's 100% ethylene oxide product is distributed in uniquely designed, recyclable, double-walled, stainless steel drums. Contract sterilizers, medical device manufacturers, and medical gas distributors are ! the Company's principal customers for this product. In addition, the Company also sells single us e canisters with 100% ethylene oxide for uses in medical dev! ice sterilization.

The Company markets and sells propylene oxide as a fumigant to aids in the control of insects and microbiological spoilage and to reduce bacterial and mold contamination in shell and processed nut meats (except peanuts), processed spices, cacao beans, cocoa powder, raisins, figs and prunes. The Company distributes its propylene oxide product primarily in recyclable, single-walled, carbon steel cylinders The Company also sells propylene oxide to customers seeking smaller quantities and whose requirements include utilization in various chemical synthesis applications, to make paints more durable and for manufacturing specialty starches and textile coatings.

Animal Nutrition & Health

The Company's Animal Nutrition & Health (ANH) segment provides the animal nutrition and health markets with products derived from the Company's microencapsulation, chelation, and basic choline chloride technologies. Commercial sales of REAS HURE Choline, a microencapsulated choline, NITROSHURETM, a microencapsulated urea, and NIASHURETM, the Company's microencapsulated niacin for dairy cows, boosts health and milk production in transition and lactating dairy cows, delivering nutrient supplements that survive the rumen and are biologically available, providing required nutritional levels. The Company's AMINOSHURE-L product, a rumen-protected lysine for use in dairy rations, gives nutritionists and dairy producers a precise and consistent source of rumen-protected lysine. The Company also markets chelated mineral supplements for uses in animal feed throughout the world. ANH also manufactures and supplies basic choline chloride, an essential nutrient for animal health, predominantly to the poultry and swine industries. The ANH segment also includes choline and certain derivatives manufactured and sold into vario! us indust! rial applications, predominately as a component for hydraulic fracturing of shale natural gas w ells, and methylamines which are a primary building block fo! r the man! ufacture of choline products and are also used in a wide range of industrial applications.

Advisors' Opinion:
  • [By John Udovich]

    Small cap ingredients stock Balchem Corporation (NASDAQ: BCPC) jumped 22.76% yesterday on news about an acquisition, meaning its worth taking a closer look at the stock along with potential peers like small cap MGP Ingredients Inc (NASDAQ: MGPI) and the PowerShares Dynamic Food & Beverage ETF (NYSEARCA: PBJ).

  • [By Jake L'Ecuyer]

    Equities Trading UP
    Balchem (NASDAQ: BCPC) shares shot up 15.27 percent to $60.08 after the company announced its plans to acquire SensoryEffects for $567 million.

  • [By Lisa Levin]

    Balchem (NASDAQ: BCPC) surged 13.56% to $59.19. The volume of Balchem shares traded 499% higher than normal. Balchem announced its plans to aquire SensoryEffects for $567 million.

  • [By Jake L'Ecuyer]

    Equities Trading UP
    Balchem (NASDAQ: BCPC) shares shot up 14.18 percent to $59.51 after the company announced its plans to acquire SensoryEffects for $567 million.

  • source from Top Stocks For 2015:http://www.topstocksblog.com/top-10-asian-stocks-to-watch-for-2016-2.html

Wednesday, July 1, 2015

Top 5 China Companies To Buy For 2016

Top 5 China Companies To Buy For 2016: China Gerui Advanced Materials Group Limited(CHOP)

China Gerui Advanced Materials Group Limited engages in the manufacture and sale of cold-rolled narrow strip steel products in the People's Republic of China. The company converts steel manufactured by third parties into thin steel sheets and strips. It sells its products directly to its customers in a range of industries, including food and industrial packaging, construction and household decorations materials, electrical appliances, and telecommunications wires and cables industries. The company was formerly known as Golden Green Enterprises Limited and changed its name to China Gerui Advanced Materials Group Limited in December 2009. China Gerui Advanced Materials Group Limited is based in Zhengzhou, China.

Advisors' Opinion:
  • [By Monica Gerson]

    China Gerui Advanced Materials Group (NASDAQ: CHOP) is expected to report its Q2 earnings.

    Ambarella (NASDAQ: AMBA) is estimated to post its Q2 earnings at $0.28 per share on revenue of $44.67 million.

  • [By Jake L'Ecuyer]

    Leading and Lagging Sectors
    On Tuesday, the basic materials sector proved to be a source of strength for the US market after Yellen statement. Huntsman (NYSE: HUN) shares surged 2.62 percent after reporting strong quarterly earnings, while China Gerui Advanced Materials Group (NASDAQ: CHOP) gained around 2.5 percent.

  • source from Top Stocks For 2015:http://www.topstocksblog.com/top-5-china-companies-to-buy-for-2016.html

Tuesday, June 30, 2015

Top 5 Diversified Bank Stocks To Own Right Now

Top 5 Diversified Bank Stocks To Own Right Now: ProShares Trust II (YCS)

ProShares Trust II (the Trust) is a statutory trust organized into separate series. The Trust offers seven Funds. The Trust offers beneficial interest in each of its 24 series. The 24 separate series include ProShares Ultra DJ-UBS Commodity, ProShares UltraShort DJ-UBS Commodity, ProShares Ultra DJ-UBS Crude Oil, ProShares UltraShort DJ-UBS Crude Oil, ProShares Ultra DJ-UBS Natural Gas, ProShares Short DJ-UBS Natural Gas, ProShares UltraShort DJ-UBS Natural Gas, ProShares Short Gold, ProShares Ultra Gold, ProShares UltraShort Gold, ProShares Ultra Silver, ProShares UltraShort Silver, ProShares Ultra Euro, ProShares UltraShort Euro, ProShares Ultra Yen ProShares UltraShort Yen, ProShares Ultra VIX Short-Term Futures ETF, ProShares VIX Short-Term Futures ETF, ProShares Short VIX Short-Term Futures ETF, ProShares UltraShort VIX Short-Term Futures ETF, ProShares Ultra VIX Mid-Term Futures ETF, ProShares VIX Mid-Term Futures ETF, ProShares Short VIX Mid-Term Futures ETF and Pro Shares UltraShort VIX Mid-Term Futures ETF.

The Funds offer investors the opportunity to obtain leveraged, inverse or inverse leveraged exposure to a particular benchmark. The Funds include funds linked to futures-based commodity indexes (the Commodity Index Funds), particular commodities (the Commodity Funds) or particular currencies (the Currency Funds). ProShare Capital Management LLC serves as the Trusts Sponsor, commodity pool operator and commodity trading advisor. Wilmington Trust Company is the sole Trustee of the Trust.

Dow Jones-UBS Commodity Index

ProShares Ultra DJ-UBS Commodity and ProShares UltraShort DJ-UBS Commodity are designed to track a multiple or an inverse multiple of the daily performance of the Dow Jones-UBS Commodity IndexSM. The Dow Jones-UBS Commodity IndexSM (the Dow Jones-UBS) is designed to be a highly liquid and diversified benchmark for the commodity futures market. It focuses to! reflect the overall c ommodity sector by measuring the performance of commodity fu! tures contracts. The Dow Jones-UBS is a rolling index, which means that the Dow Jones-UBS does not take actual physical possession of any commodities; rather, it tracks a rolling futures position. An investor with a rolling futures position is able to avoid delivering (or taking delivery of) underlying physical commodities while maintaining exposure to those commodities. The roll for each Index component occurs over a period of five Dow Jones-UBS business days in certain months according to a pre-determined schedule. The exact roll methodology differs between certain commodities. The Index will reflect the performance of its underlying commodities, including roll costs, without regard to income earned on cash positions. The Dow Jones-UBS is consisted of eight different commodity sectors, such as petroleum, natural gas, livestock, grains, industrial metals, precious metals, softs and vegetable oils. These eight sectors track futures contracts prices of 19 specific commodities , such as natural gas, crude oil, unleaded gasoline, heating oil, live cattle, lean hogs, wheat, corn, soybeans, soybean oil, aluminum, copper, zinc, nickel, gold, silver, sugar, cotton and coffee. The Dow Jones-UBS is consisted of commodities traded on the United States exchanges, with the exception of aluminum, nickel and zinc, which trade on the London Metal Exchange.

Dow Jones-UBS Natural Gas Subindex

ProShares Ultra DJ-UBS Natural Gas and ProShares UltraShort DJ-UBS Natural Gas are designed to track twice (2x) or twice the inverse (-2x) of the daily performance of the Dow Jones-UBS Natural Gas SubindexSM, respectively The Dow Jones-UBS Natural Gas SubindexSM is intended to reflect the performance of a rolling position in natural gas futures contracts traded on the NYMEX without regard to income earned on cash positions. An investment in natural gas futures contracts may often perform very differently than the price ! of physic! al natural gas.

Advisors' Opinion:
  • [By Matthew McCall]

    An ETF that takes advantage of a weak yen is the ProShares UltraShort Yen ETF (NYSE: YCS). The ETF returns two times the daily inverse of the value of the yen. For example, if the yen declines by 0.5 percent, theoretically YCS should be up 1.0 percent and vice versa. The leveraged aspect of the ETF makes it too risky for most investors and it should only be considered a short-term trading vehicle.

  • [By Ben Levisohn]

    The euro has dropped about 0.8% against the dollar, while the CurrencyShares Euro Trust ETF (FXE) has dropped 0.7% to $136.71 and the Currency Shares Japanese Yen Trust ETF (FXY) has fallen 1%. The ProShares UltrasShort Euro ETF (EUO) has gained 1.3% to $16.77, while the ProShares UltraShort Yen (YCS) has gained 1.9% to $66.58.

  • [By Anthony Mirhaydari]

    Today, the yen carry trade, as represented by the ProShares UltraShort Yen (YCS) , is collapsing below both its lower Bollinger Band and its 50-day moving average the most significant downtrend initiation since June. The scramble to cover positions funded by yen carry trades is why the selling is so frantic.

  • [By MONEYMORNING]

    Split your capital in two halves. With one half, buy ProShares UltraShort Yen (NYSE Arca: YCS), and with other half, buy shares of AMLP, simple and clean.

  • source from Top Penny Stocks For 2015:http://www.seekpennystocks.com/top-5-diversified-bank-stocks-to-own-right-now.html

Monday, June 29, 2015

Top 10 Performing Companies To Watch In Right Now

Top 10 Performing Companies To Watch In Right Now: Gilead Sciences Inc.(GILD)

Gilead Sciences, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for the treatment of life threatening diseases worldwide. Its products include Atripla, Truvada, Viread, Emtriva for the treatment of human immunodeficiency virus infection in adults; Hepsera, an oral formulation for the treatment of chronic hepatitis B; AmBisome, a amphotericin B liposome injection to treat invasive fungal infections; Letairis, an endothelin receptor antagonist for the treatment of pulmonary arterial hypertension; Ranexa for the treatment of chronic angina; Vistide, an antiviral medication for the treatment of cytomegalovirus retinitis in patients with AIDS; and Cayston, an inhaled antibiotic used as a treatment to enhance respiratory systems. The company?s products also comprise Tamiflu, an oral antiviral for the treatment and prevention of influenza A and B; Macugen, an intravitreal injection for the treatment of neovascular a ge-related macular degeneration; and Lexiscan/Rapiscan, an injection used as a pharmacologic stress agent in radionuclide myocardial perfusion imaging. Its products under the Phase III clinical trials consist of Cobicistat, a pharmacoenhancer that is under evaluation as a boosting agent for HIV medicines; Elvitegravir, an oral integrase inhibitor being evaluated as part of combination therapy for HIV; Integrase Single-Tablet, a ?Quad? regimen of elvitegravir, cobicistat, tenofovir disoproxil fumarate, and emtricitabine for the treatment of HIV/AIDS in treatment-naive patients; and Aztreonam for inhalation solution for the treatment of cystic fibrosis patients with Pseudomonas aeruginosa. The company?s Phase II clinical trials products comprise Cicletanine, Ranolazine, and Aztreonam, as well as GS 9190, GS 9256, and GS 9451. Its Phase I clinical trial products include GS 7340, GS 5885, GS 6620, GS 9620, and GS 6624. The company was founded in 198! 7 and is headquartered in Fos t er City, California.

Advisors' Opinion:
  • [By Ben Levisohn]

    Remember when biotech stocks like Gilead Sciences (GILD) and Celgene (CELG) were getting creamed and everyone was wondering if the biotech boom was finished? Yeah, neither do I.

    We’d better refresh our memories, however. The iShares Nasdaq Biotechnology ETF (IBB) has rallied 20% since dropping 21% from the February 25 through April 11. And large-cap biotech stocks now trade at 16.3 times 2015 earnings versus the S&P 500′s 14.8 times. That, says Nomura’s M. Ian Somaiya and team makes beating earnings forecasts an imperative, who says “lackluster 1Q earnings have increased reliance on solid 2Q results to maintain momentum in the group.”

    Somaiya points to Gilead Sciences, Alexion Pharmaceuticals (ALXN), Celgene and Incyte (INCY) as the biotech companies most likely to beat earnings:

    For Gilead Sciences, we believe Sovaldi sales reach $3bn, almost 2x our $1.6bn and above the Streets $2.6bn estimates, based on strength of prescription data. For Alexion Pharmaceuticals, we believe upside will come from a higher-than-expected rate of patient starts in ROW territories for PNH, a $1-2bn opportunity, and Europe for aHUS. For Celgene, we believe 2Q revenue estimates could be understated due to 1Q seasonality and inventory drawdowns, setting up for a potential beat in Revlimid, Pomalyst and Abraxane. For Incyte, we expect Jakafi sales to bounce back in 2Q, given inventories returned to the low end of the normal range, gross-to-net returns to the 9-10% guidance, and a 4.75% price increase on 1 April. In addition, data presentations at ASCO could have increased off-label usage in pancreatic cancer and PV.

    Shares of Gilead Sciences have gained 1.4% to $89.96 at 1:26 p.m., Alexion Pharmaceuticals has risen 0.6% to $164.22, Incyte has advanced 1% to $51.34 and Celgene has fallen 0.8% to $84.46. The iShares Nasdaq Biotechnology ET! F is up 0! .6% at $258.33.

  • [By John Kimelman]

    In the health-care sector, shares of biotech company Gilead Sciences (GILD) fell 3.45% on the day, following a 14% drop Monday. Gilead has been hit by news tha Express Scripts will make an AbbVie drug the exclusive option for patients with the most common form of hepititas C. AbbVie is a direct rival of Gilead.

  • [By Sean Williams]

    For shareholders of Gilead Sciences (NASDAQ: GILD  ) it's practically been a dream year. Shares rose close to 40%, tacking on roughly $45 billion in market value, following the successful approval and launch of oral hepatitis C drugs Sovaldi and Harvoni.

  • [By John Udovich]

    At the end of this week,congressional scrutiny was weighting down large cap biotech Gilead Sciences, Inc (NASDAQ: GILD) and dragging down much of the biotech sector, but there was still good news surrounding small cap biotech stocks like Endocyte, Inc (NASDAQ: ECYT), Aastrom Biosciences Inc (NASDAQ: ASTM)and TNI BioTech (OTCMKTS: TNIB) plus there were more biotech IPOs which debuted:

  • source from Top Stocks To Buy For 2015:http://www.topstocksforum.com/top-10-performing-companies-to-watch-in-right-now-3.html

Wednesday, June 24, 2015

10 Best Income Stocks To Buy Right Now

10 Best Income Stocks To Buy Right Now: Suntory Beverage & Food Ltd (STBFY)

Suntory Beverage & Food Limited is principally engaged in the manufacture and sale of beverages and food. The Company operates in two geographical segments. The Domestic segment is engaged in the manufacture and sale of various soft drinks within Japan, such as coffee drinks, mineral water, green tea drinks, tea drinks, carbonated drinks, fruit juice drinks, functional beverages, milk beverages, and food for specified health use, as well as syrup for general and business usage. The International segment is engaged in the manufacture and sale of carbonated drinks, fruit juice drinks, health food, seasoning, tea-based beverages and others, with operations in Europe, Oceania, Asia and the Americas. As of May 29, 2013, the Company had 80 subsidiaries and 10 associated companies. On October 15, 2013, the Company acquired Lucozade Ribena Suntory Limited. On December 12, 2013, the Company acquired Suntory Beverage & Food Europe Limited. Advisors' Opinion:
  • [By Charles Sizemore]

    Lets start with Suntory Beverage & Food Limited (STBFY),which recently completed its acquisition ofBeam Inc., formerly the purest play on bourbon. Beam was the owner of the eponymous Jim Beam brand, as well as the higher-end Makers Mark and Knob Creek and the lower-end Old Crow.Suntory is Japans leading spirits company, though most Americans will be unfamiliar with its Japanese whisky brands, such as Yamazaki and Hakushu. (Note for booze snobs: Japanese whiskylike Scotch and Canadian whiskyis correctly spelled whisky. American bourbon, Tennessee whiskey and Irish whiskey are correctly spelled whiskey.)

  • [By John Udovich]

    Whiskey has become increasingly cool and popular thanks to the whole cocktail movement, something thats good for big whiskey stocks like Suntory Beverage & Food Limited (OTCMKTS: STBFY), Diageo plc (NYSE: DEO) and Brown-Forman Corporation (NYSE: BF.B) whoalso produce a wide varie! ty ofliquors and beverages. In fact,a recent episode of theDaily Tickercited these stats from a USA Today article:

  • source from Top Stocks To Buy For 2015:http://www.topstocksforum.com/10-best-income-stocks-to-buy-right-now.html

Sunday, June 21, 2015

10 Best Biotech Stocks To Invest In 2015

Discount Dental Materials, Inc. (DDOO)

Today, DDOO remains (0.00%) +0.000 at $1.00 thus far (ref. google finance Delayed: 10:12AM EDT�June 25, 2013).

Bond Laboratories, Inc. previously reported NDS launched two exciting new products at the annual GNC庐 Global Franchise Convention.

Cerebain Biotech Corp. a subsidiary of Discount Dental Materials, Inc. previously reported the appointment of Dr. Surinder Saini as Chairman of its Scientific Advisory Board. The advisory board provides key clinical insight into the company�� efforts to develop and commercialize a novel approach to the treatment for patients suffering from Alzheimer�� disease. Dr. Saini is the lead scientist behind the development of the world’s first medical device specifically designed for the treatment of Alzheimer�� disease utilizing the Omentum

Take a look at Discount Dental Materials, Inc. (DDOO) 5 day chart:

Top 5 Wireless Telecom Companies To Buy Right Now: Intellicell Biosciences Inc (SVFC)

Intellicell Biosciences, Inc., formerly Media Exchange Group, Inc., incorporated on March 8, 1999, is engaged in regenerative medicine company focused on the expanding regenerative medical markets using a process to separate adult autologous vascular cells (AAVC's) from blood vessels in adult adipose (fat) tissue. The Company is also exploring and undertaking, either on its own or in collaboration with a third party, providing a service for the collection, processing and storage of autologous cells for future use. As of December 31, 2011, the Company has developed technologies that allow reproducible separation of stromal vascular fraction (IntelliCell) containing adipose stem cells that can be performed in tissue processing centers and in doctors��offices. On June 3, 2011, the Company completed the acquisition of Intellicell Biosciences, Inc. The Company formed a wholly-owned subsidiary, ICBS Research, Inc.

The Company's process involves the application of ultrasonic cavitation (sound waves) to the extracted adipose tissue, which results in the separation AAVC's from the blood vessels in adult adipose (fat) tissue. This AAVC, or stromal vascular fraction (IntelliCells), are removed from the patient at the point of care, and separated at the point of care under the supervision of its certified technicians following current good manufacturing practices (cGMPs) and current good tissue practices (cGTPs), and the cells are then returned to the medical professionals at the point of care for use a patient's own body (autologous treatment), by way of a same-day clinical procedure for homologous use of these cells.

Intellicell Biosciences, Inc., formerly Media Exchange Group, Inc., incorporated on March 8, 1999, is engaged in regenerative medicine company focused on the expanding regenerative medical markets using a process to separate adult autologous vascular cells (AAVC's) from blood vessels in adult adipose (fat) tissue. The Company is also exploring and undertaking, either on ! its own or in collaboration with a third party, providing a service for the collection, processing and storage of autologous cells for future use. As of December 31, 2011, the Company has developed technologies that allow reproducible separation of stromal vascular fraction (IntelliCell) containing adipose stem cells that can be performed in tissue processing centers and in doctors��offices. On June 3, 2011, the Company completed the acquisition of Intellicell Biosciences, Inc. The Company formed a wholly-owned subsidiary, ICBS Research, Inc.

The Company's process involves the application of ultrasonic cavitation (sound waves) to the extracted adipose tissue, which results in the separation AAVC's from the blood vessels in adult adipose (fat) tissue. This AAVC, or stromal vascular fraction (IntelliCells), are removed from the patient at the point of care, and separated at the point of care under the supervision of its certified technicians following current good manufacturing practices (cGMPs) and current good tissue practices (cGTPs), and the cells are then returned to the medical professionals at the point of care for use a patient's own body (autologous treatment), by way of a same-day clinical procedure for homologous use of these cells.

The Company competes with Cytori Therapeutics, Stem Cell Assurance, Inc., Osiris, Aastrom Biosciences, Aldagen, BioTime, Baxter International, Celgene, Geron, Harvest Technologies, Mesoblast, Regenexx, NeoStem, X-Cell Center, Stem Cells, Athersys, and Tissue Genesis, Life Technologies, Asterand, pacific biosciences of california inc. and AllCells, LLC.

Advisors' Opinion:
  • [By Bryan Murphy]

    To say that shares of IntelliCell BioSciences, Inc. (OTCMKTS:SVFC) has been disappointing since 2011 would be an understatement. SVFC has been an outright disaster since 2011, falling from a peak of $19.00 to a low of, well, just a few pennies as of late last year. In fact, there are those who are understandably wondering how the company is still alive, only producing about a half a million dollars in revenue in 2012, and then dialing that figure back down to nothing for the last few quarters. Yet, there's just something about a company that refuses to go away.... something compelling now.

  • [By Bryan Murphy]

    Well, though I give myself a C for timing, it looks like I'm going to be able to give myself an A for stock-picking. Back on January 27th I deemed IntelliCell BioSciences, Inc. (OTCMKTS:SVFC) was a compelling buy, and though SVFC was stagnant for a month after that, it looks like the stock's finally getting on its horse. If you didn't get it then, you may want to get in now.

10 Best Biotech Stocks To Invest In 2015: Cell Therapeutics Inc (CTIC)

Cell Therapeutics, Inc. (CTI), incorporated in 1991, develops, acquires and commercializes treatments for cancer. The Company�� research, development, acquisition and in-licensing activities concentrate on identifying and developing new ways to treat cancer. As of December 31, 2011, CTI focused its efforts on Pixuvri (pixantrone dimaleate) (Pixuvri), OPAXIO (paclitaxel poliglumex) (OPAXIO), tosedostat, brostallicin and bisplatinates. As of December 31, 2011, it developed Pixuvri, an anthracycline derivative for the treatment of hematologic malignancies and solid tumors. Another late-stage drug candidate of the Company, OPAXIO, is being studied as a potential maintenance therapy for women with advanced stage ovarian cancer, who achieve a complete remission following first-line therapy with paclitaxel and carboplatin. As of December 31, 2011, it also developed tosedostat in collaboration with Chroma Therapeutics, Ltd. (Chroma). On May 31, 2012, CTI completed its acquisition gaining worldwide rights to S*BIO Pte Ltd.'s (S*BIO) pacritinib.

Pixuvri

As of December 31, 2011, the Company developed Pixuvri, an aza-anthracenedione derivative, for the treatment of non-Hodgkin�� lymphoma (NHL), and various other hematologic malignancies, and solid tumors. Pixuvri was studied in the Company�� EXTEND, or PIX301, clinical trial, which was a phase III single-agent trial of Pixuvri for patients with relapsed, refractory aggressive NHL who received two or more prior therapies and who were sensitive to treatment with anthracyclines. On September 28, 2011, CTI announced that a second independent radiology assessment of response and progression endpoint data from its PIX301 clinical trial of Pixuvri was achieved with statistical significance. The results of the EXTEND trial met its primary endpoint and showed that patients randomized to treatment with Pixuvri achieved a significantly higher rate of confirmed and unconfirmed complete response compared to patients treated with standard chem! otherapy had a significantly increased overall response rate and experienced a statistically significant improvement in median progression free survival. Pixuvri had predictable and manageable toxicities when administered at the proposed dose and schedule in the EXTEND clinical trial in heavily pre-treated patients. In March 2011, the Company initiated the PIX-R trial to study Pixuvri in combination with rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL). Pixuvri has also been studied in patients with HER2-negative metastatic breast cancer who have tumor progression after at least two, but not more than three, prior chemotherapy regimens. In the second quarter of 2010, the NCCTG opened this phase II study for enrollment. The study is closed to accrual and results are expected to be reported by the NCCTG later in 2012.

OPAXIO

OPAXIO is the Company�� biologically-enhanced chemotherapeutic agent that links paclitaxel to a biodegradable polyglutamate polymer, resulting in a new chemical entity. As of December 31, 2011, the Company focused its development of OPAXIO on ovarian, brain, esophageal, head and neck cancer. OPAXIO was designed to improve the delivery of paclitaxel to tumor tissue while protecting normal tissue from toxic side effects. In November 2010, results were presented by the Brown University Oncology Group from a phase II trial of OPAXIO combined with temozolomide (TMZ), and radiotherapy in patients with newly-diagnosed, high-grade gliomas, a type of brain cancer. The trial demonstrated a high rate of complete and partial responses and a high rate of six month progression free survival (PFS). Based on these results, the Brown University Oncology Group has initiated a randomized, multicenter, phase II study of OPAXIO and standard radiotherapy versus TMZ and radiotherapy for newly diagnosed patients with glioblastoma with an active gene termed MGMT that reduces responsiveness to TMZ. A phase I/II study of OPAXIO combined with radi! otherapy ! and cisplatin was initiated by SUNY Upstate Medical University, in patients with locally advanced head and neck cancer.

Tosedostat

In March 2011, the Company entered into a co-development and license agreement with Chroma Therapeutics, Ltd. (Chroma), providing the Company with marketing and co-development rights to Chroma�� drug candidate, tosedostat, in North, Central and South America. Tosedostat is an oral, aminopeptidase inhibitor that has demonstrated anti-tumor responses in blood related cancers and solid tumors in phase I-II clinical trials. Interim results from the phase II OPAL study of tosedostat in elderly patients with relapsed or refractory acute myeloid leukemia (AML) showed that once-daily, oral doses of tosedostat had predictable and manageable toxicities and results demonstrated response rates, including a high-response rate among patients who received prior hypomethylating agents, which are used to treat myelodysplastic syndrome (MDS), a precursor of AML.

Brostallicin

As of December 31, 2011, the Company developed brostallicin through its wholly owned subsidiary, Systems Medicine LLC, which holds rights to use, develop, import and export brostallicin. Brostallicin is a synthetic deoxyribonucleic acid (DNA) minor groove binding agent that has demonstrated anti-tumor activity and a favorable safety profile in clinical trials, in which more than 230 patients have been treated as of December 31, 2011. The Company uses a genomic-based platform to guide the development of brostallicin. A phase II study of brostallicin in relapsed, refractory soft tissue sarcoma met its predefined activity and safety hurdles and resulted in a first-line phase II clinical trial study that was conducted by the European Organization for Research and Treatment of Cancer (EORTC).

The Company competes with Bristol-Myers Squibb Company, Sanofi-Aventis, Pfizer, Roche Group, Genentech, Inc., Astellas Pharma, Eli Lilly and Company, Celgene, Telik, I! nc., TEVA! Pharmaceuticals Industries Ltd. and PharmaMar.

Advisors' Opinion:
  • [By Bryan Murphy]

    Like it or not, all good things must come to an end.... even for a red hot stock like Cell Therapeutics Inc. (NASDAQ:CTIC). Yes, CTIC is up 111% since the end of 2013, up 14% today alone, and it doesn't look like the bulls have any reason to slow down now. That's exactly why now's the time for current shareholders to be afraid, however - expect it when you least expect it.

10 Best Biotech Stocks To Invest In 2015: Biota Pharmaceuticals Inc (BOTA)

Biota Pharmaceuticals, Inc., formerly Nabi Biopharmaceuticals, incorporated on March 14, 1969, is an anti-infective drug development company, with key expertise in respiratory diseases, particularly influenza. Biota developed the neuraminidase inhibitor, zanamivir, subsequently marketed by GlaxoSmithKline as Relenza. The Company�� researches include a series of candidate drugs aimed at treatment of respiratory syncytial virus (RSV) disease and Hepatitis C (HCV) virus infections. In addition, Biota and Daiichi Sankyo co-own a range of second generation influenza anti-virals, of which the lead product lnavir, is approved for marketing in Japan.

The Company�� products include Zanamivir, Inavi, Phoslyra, BioStar OIA FLU and BioStar OIA FLU A/B. Zanamivir is a neuraminidase inhibitor for the treatment and prophylaxis of influenza marketed as Relenza by GlaxoSmithKline. Inavi (laninamivir) is a neuraminidase inhibitor marketed by Daiichi Sankyo in Japan. Phoslyra is a phosphate binder indicated to reduce serum phosphorus in patients with end stage renal disease (ESRD). BioStar OIA FLU and BioStar OIA FLU A/B are influenza diagnostic tests, which are marketed by Inverness Medical as part of their BioStar product range.

Relenza is delivered directly to the primary site of infection on the lungs, using a Disk Inhaler device. Relenza is approved in over 50 countries for the treatment of influenza, including in the United States, the European Union, Japan and Australia. Relenza is also approved for use as a preventative (prophylactic) treatment against influenza. Inavir is approved for sale in Japan for the treatment of influenza in adults and children. Daiichi Sankyo has applied to sell Inavir in Japan for the prevention of influenza.

PhosLo and Phoslyra are different dose forms of calcium acetate; a phosphate binder approved in multiple countries for the control of hyperphosphatemia (high serum phosphate) in patients with end stage renal disease (ESRD). PhosLo and Pho! slyra were sold to Fresnius Medical Care. Biota, together with its Japanese based partner, Daiichi Sankyo, have developed an inhaled antiviral compounds for influenza, called long acting inhaled neuraminidase inhibitors (LANI). Biota's human rhinovirus (HRV) drug for the prevention and treatment of the causes of the common cold, BTA798, has completed Phase I, Phase IIa and Phase IIb clinical trials.

Advisors' Opinion:
  • [By gurujx]

    Biota Pharmaceuticals Inc (BOTA) Reached the 3-year Low of $2.42

    The prices of Biota Pharmaceuticals Inc (BOTA) shares have declined to close to the 3-year low of $2.42, which is 93.3% off the 3-year high of $34.92.

10 Best Biotech Stocks To Invest In 2015: Pharmacyclics Inc (PCYC)

Pharmacyclics, Inc., incorporated on April 19, 1991, is a clinical-stage biopharmaceutical company focused on developing and commercializing small-molecule drugs for the treatment of cancer and immune mediated diseases. The Company's clinical development and product candidates are small-molecule enzyme inhibitors designed to target biochemical pathways involved in human diseases. As of June 30, 2011, it had three drug candidates under clinical development and a number of preclinical lead molecules. This includes an inhibitor of Bruton�� tyrosine kinase (Btk) (PCI-32765) in Phase II studies in hematologic malignancies; a Btk inhibitor lead optimization program targeting autoimmune indications, an inhibitor of Factor VIIa (PCI-27483) in a Phase II clinical trial in pancreatic cancer, and a histone deacetylase (HDAC) inhibitor (PCI-24781) in Phase I and II clinical trials in solid tumors and hematological malignancies as of June 30, 2012.

As of June 30, 2012, the Company developed ibrutinib, which has demonstrated clinical activity and tolerability in Phase I and Phase II clinical trials in a variety of B-cell malignancies, including chronic lymphocytic leukemia (CLL) and a number of non-Hodgkin�� lymphoma (NHL) subtypes. CLL, mantle cell lymphoma (MCL), follicular lymphoma (FL), diffuse B-cell lymphoma (DLBCL) and multiple myeloma (MM) are specific indications of its current or planned Phase Ib/II and Phase III development program. had development programs for B-cell malignancies and autoimmune diseases. For malignant indications it has developed PCI-32765, which has demonstrated clinical activity and tolerability in Phase I and Phase II clinical trials in a range of B-cell malignancies, including chronic lymphocytic leukemia (CLL) and a number of non-Hodgkin�� lymphoma (NHL) subtypes. CLL, mantle cell lymphoma (MCL), follicular lymphoma (FL), diffuse large B cell lymphoma (DLBCL) and multiple myeloma (MM) are specific indications of its Phase II development. It has developed an assay! to measure occupancy of Btk in PBMCs using a cell-permeable fluorescently-labeled derivative of PCI-32765.

Factor VII is an enzyme that becomes activated (FVIIa) by binding to the cell surface protein tissue factor (TF), a protein found in the body that helps to trigger the process of blood clotting in response to injury. TF is over expressed in many cancers including gastric, breast, colon, lung, prostate, ovarian and pancreatic cancers. In these tumors, the FVIIa/TF complex induces intracellular signaling pathways by activating protease activated receptor 2 (PAR-2), another cell-surface protein. This in turn increases the expression of interleukin-8 (IL-8), a protein produced by white blood cells and other immune cells in response to pathogenic stimulation, and vascular endothelial growth factor (VEGF), a signal protein produced by cells that stimulate the growth of blood vessels. Both proteins play an important role in tumor growth and metastases as well as angiogenesis (growth of new blood vessels). FVIIa/TF complex also initiates the coagulation (a process by which blood forms clots) processes implicated in the high incidence of thromboembolic (the process by which the blood clots within a blood vessel) complications seen in patients with TF-expressing cancers. Thromboembolic events are a cause of death in patients with cancer and anticoagulant treatment has been shown to improve survival in a variety of cancers (Klerk et al. JCO. 2005).

PCI-27483 Factor VIIa Inhibitor

The Company�� Factor VIIa inhibitor PCI-27483 is a first-in-human small molecule inhibitor that selectively targets FVIIa. As an inhibitor of FVIIa, PCI-27483 has two potential mechanisms of action: inhibition of intracellular signaling involved in tumor growth and metastases and inhibition of early coagulation processes associated with thromboembolism.

Factor VIIa PCI-27483 Clinical Development Update

A multicenter Phase I/II of PCI-27483 in patients with locally a! dvanced o! r metastatic pancreatic cancer that are either receiving or are planned to receive gemcitabine therapy has completed enrollment. The Phase II portion of the study randomized patients to receive either gemcitabine alone or gemcitabine plus PCI-27483 (1.2 mg/kg twice daily). The objectives are to assess the safety of FVIIa Inhibitor PCI-27483 at pharmacologically active dose levels, to assess potential inhibition of tumor progression and to obtain initial information of the effects on the incidence of thromboembolic events. Due to a paradigm shift away from the use of gemcitabine alone for the treatment of pancreatic cancer, enrolling patients in this randomized study has been challenging. PCYC is evaluating other alternatives for development of this agent.

A multicenter Phase I/II of PCI-27483 in patients with locally advanced or metastatic pancreatic cancer that are either receiving or are planned to receive gemcitabine therapy has completed enrollment. The Phase II portion of the study randomized patients to receive either gemcitabine alone or gemcitabine plus PCI-27483 (1.2 mg/kg twice daily). PCI-27483 is covered by United States patents and patent applications and counterpart patents and patent applications in fourteen ex-United States territories, including Europe, Canada, Mexico, Japan, China, India, South Korea, Australia and Brazil.

Advisors' Opinion:
  • [By Keith Speights]

    Last year, Pharmacyclics (NASDAQ: PCYC  ) shares gained a whopping 280%. That was enough to land the biotech a spot on The Motley Fool's list of top health-care stocks in 2012. How is 2013 looking so far? Shares have gained more than 30% year to date but have been anemic since early March.

10 Best Biotech Stocks To Invest In 2015: Incyte Corporation(INCY)

Incyte Corporation focuses on the discovery and development of proprietary small molecule drugs for hematologic and oncology indications, and inflammatory and autoimmune diseases. Its product pipe line includes INCB18424, which is in Phase III clinical trial for myelofibrosis; Phase III trial for polycythemia vera; Phase III trial for essential thrombocythemia; Phase I/II trial to treat solid tumors/other hematologic malignancies; and Phase IIb trail for the treatment of psoriasis. The company?s portfolio also includes INCB28050, a Phase IIb clinical trial product for rheumatoid arthritis; INCB28060, a Phase I/II product for solid tumors; INCB7839, a Phase II product for breast cancer; and INCB24360, a Phase I/II product for solid tumors. It has a collaborative research and license agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; and Pfizer Inc. The company was founded in 1991 and is headquartered in Wilmington, Delaware.

Advisors' Opinion:
  • [By John McCamant]

    Incyte's (INCY) crackerjack medicinal chemistry team continues to show that they can create better and differentiated drug candidates from the competition.

    The key near-term driver for INCY is Jakafi growth, and with the increased sales guidance, the company is delivering. The drug's overall profile continues to improve and the recent survival data proves that Jakafi does much more for myelofibrosis patients than just control symptoms.

  • [By John McCamant]

    Incyte Pharmaceuticals (INCY) recently held their quarterly conference call. Importantly, sales for Jakafi��n advanced compound used for the treatment of patients with intermediate or high-risk myelofibrosis (MF)��et or exceeded Wall Street's expectations.

10 Best Biotech Stocks To Invest In 2015: Merck & Company Inc.(MRK)

Merck & Co., Inc. provides various health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. The company?s Pharmaceutical segment provides human health pharmaceutical products, such as therapeutic and preventive agents for the treatment of human disorders in the areas of bone, respiratory, immunology, dermatology, cardiovascular, diabetes and obesity, infectious diseases, neurosciences and ophthalmology, oncology, vaccines, and women's health and endocrine. This segment also offers human health vaccines, such as preventive pediatric, adolescent, and adult vaccines. Its Animal Health segment discovers, develops, manufactures, and markets animal health products. This segment offers antibiotics, anti-inflammatory products, vaccines, products for the treatment of fertility disorders, and parasiticides for cattle, swine, horses, poultry, dogs, cats, salmons, and fish. The Consumer Care segment develops, manufac tures, and markets over-the-counter, foot care, and sun care products. Its over-the-counter product line includes non-drowsy antihistamines; treatment for occasional constipation; decongestant-free cold/flu medicine for people with high blood pressure; nasal decongestant spray; and treatment for frequent heartburn. This segment?s foot care products comprise topical antifungal, and foot and sneaker odor/wetness products; and sun care products include sun care lotions, sprays and dry oils; and sunburn relief products. The company serves drug wholesalers and retailers, hospitals, government agencies, physicians, physician distributors, veterinarians, animal producers, and managed health care providers, as well as food chain and mass merchandiser outlets in the United States and Canada. Merck & Co., Inc. was founded in 1891 and is headquartered in Whitehouse Station, New Jersey.

Advisors' Opinion:
  • [By Maxx Chatsko]

    One company that is about to face the brunt of its patent cliff exposure is Merck (NYSE: MRK  ) , which is set to lose exclusivity for its former megablockbuster Singulair in its last major worldwide markets this year. There are still some interesting molecules in the pipeline and several major approvals pending. However, I don't think Merck stock is worth owning. Here are a few reasons why.

  • [By Value Line]

    The biggest contributors for the year so far were the aforementioned Intel (up 34.1%) and Microsoft (up 23.9%). The Dogs are also contending for a Canine Trifecta, of sorts, counting the three highest performing Industrials amongst their pack; the third being Merck & Co. (MRK), up 18.4%. The drugmaker�� top line has been in decline for three years now, due to patent losses. However, the company has been able to stem the profit erosion through growth in its core franchises.

  • [By Laura Brodbeck]

    Earnings reports expected on Monday include:

    Merck & Company, Inc. (NYSE: MRK) is expected to report third quarter EPS of $0.88 on revenue of $11.19 billion, compared to last year�� EPS of $0.95 on revenue of $11.49 billion. Apple Inc. (NASDAQ: AAPL) is expected to report EPS of $7.88 on revenue of $36.76 billion, compared to last year�� EPS of $8.67 on revenue of $35.97 billion. Biogen Idec Inc. (NASDAQ: BIIB) is expected to report third quarter EPS of $2.10 on revenue of $1.78 billion, compared to last year�� EPS of $1.91 on revenue of $1.39 billion. Herbalife LTD. (NYSE: HLF) is expected to report third quarter EPS of $1.14 on revenue of $1.20 billion, compared to last year�� EPS 0f $1.04 on revenue of $1.02 billion.

    Economics

  • [By Keith Speights]

    Although it has no commercialized drugs to generate revenue, Lexicon has been able to keep going through the years by forming relationships with larger organizations. For example, Lexicon and Merck (NYSE: MRK  ) have worked together for several years to develop biotherapeutic drugs. The partnership with Merck has netted Lexicon $52.5 million in revenue for development.

10 Best Biotech Stocks To Invest In 2015: GW Pharmaceuticals PLC (GWPRF)

GW Pharmaceuticals plc is a United Kingdom-based company. The Company is engaged in the research, development and commercialization of a range of cannabinoid prescription medicines to meet patient needs in a range of medical conditions. The Company is developing a portfolio of cannabinoid medicines, of which the main product is Sativex, an oromucosal spray for the treatment of Multiple Sclerosis (MS) symptoms, cancer pain and neuropathic pain. The Company operates in three segments: Sativex Commercial, Sativex Research and Development and Pipeline Research and Development. The Company�� wholly owned subsidiaries include GW Pharma Limited, G-Pharm Limited, Cannabinoid Research Institute Limited, Guernsey Pharmaceuticals Limited and GWP Trustee Company Limited. Advisors' Opinion:
  • [By Ben Levisohn]

    But, as the Huffington Post points out, most of the companies that stand to benefit are very small–they make micro caps look big–trade over the counter–good bye liquidity. That includes transaction-processing company MediSwipe (MWIPD), GreenGro Technologies (GRNH) Medbox (MDBX), which makes dispenser for high-risk drugs, and GW Pharmaceuticals (GWPRF).

Thursday, June 18, 2015

Hot Cheapest Companies To Invest In 2015

With shares of Amazon (NASDAQ:AMZN) trading around $311, is AMZN an OUTPERFORM, WAIT AND SEE, or STAY AWAY? Let�� analyze the stock with the relevant sections of our CHEAT SHEET investing framework.

T = Trends for a Stock’s Movement

Amazon serves its customers through its retail websites and focus on selection, price, and convenience. The company also manufactures and sells Kindle devices. Amazon offers programs that enable sellers to sell their products on the company�� websites, including the sellers��own branded websites, and fulfill orders through them. Amazon also provides platforms that allow authors, musicians, filmmakers, app developers, and others to publish and sell content. Online commerce has been on the rise because of the convenience, efficiency, and relatively low prices offered.

Amazon unveiled its new Kindle Fire HDX tablets, one with a 7-inch screen and one with a 8.9-inch screen, late on Tuesday night. Amazon�� new Kindle devices are lighter and faster with more memory and longer battery life, according to a report from The New York Times. If users did nothing but read using the 8.9-inch model, the battery life would supposedly last 17 hours. The cheapest of the new Kindle Fire tablets will cost $139. Amazon is releasing the tablets into a competitive market that�� dominated by Apple�� (NASDAQ:AAPL) iPad.

10 Best Safest Stocks To Watch Right Now: Tidewater Inc.(TDW)

Tidewater Inc., through its subsidiaries, provides offshore service vessels and marine support services to the offshore energy industry through the operation of a fleet of marine service vessels. It provides services in support of offshore exploration, field development, and production, including towing of and anchor handling for mobile offshore drilling units; transporting supplies and personnel necessary to sustain drilling, workover, and production activities; offshore construction and seismic support; and various specialized services, such as pipe and cable laying. The company?s vessels include platform supply vessels, and anchor handling towing supply vessels that are used in transporting supplies and equipment from shore bases to deepwater and intermediate water depth offshore drilling rigs, platforms, and other installations; towing-supply and supply vessels used in intermediate and shallow waters; and crewboats and utility vessels that are chartered for transporti ng personnel and supplies from shore bases to offshore drilling rigs, platforms, and other installations. It also operates offshore tugs used for towing floating drilling rigs; assisting in the docking of tankers; towing barges; assisting in pipe laying, cable laying, and construction barges; and commercial towing operations, including towing barges carrying various bulk cargoes and containerized cargo. In addition, the company operates inshore tugs; production, line-handling, and various other special purpose vessels. Further, it operates two shipyards, which construct, modify, and repair vessels. As of March 31, 2011, the company had 378 vessels serving the global offshore energy industry. The company has operations in the United States, Gulf of Mexico, the Persian/Arabian Gulf, and areas offshore Australia, Brazil, Egypt, India, Indonesia, Malaysia, Mexico, Trinidad, Venezuela, and West Africa. Tidewater Inc. was founded in 1956 and is headquartered in New Orleans, Louisi ana.

Advisors' Opinion:
  • [By Traders Reserve]

    For investors who want a piece of this developing trend, Transocean and Seadrill are two of the bigger players in this arena. Other offshore drillers/rig operators are Noble (NE) and Ensco (ESV). Companies that provide services to offshore drillers and benefit from increases in exploration and drilling activity are Gulfmark Offshore (GLF), Hornbeck (HOS), Seacor (CKH) and Tidewater (TDW).

  • [By Seth Jayson]

    When judging a company's prospects, how quickly it turns cash outflows into cash inflows can be just as important as how much profit it's booking in the accounting fantasy world we call "earnings." This is one of the first metrics I check when I'm hunting for the market's best stocks. Today, we'll see how it applies to Tidewater (NYSE: TDW  ) .

  • [By Seth Jayson]

    Calling all cash flows
    When you are trying to buy the market's best stocks, it's worth checking up on your companies' free cash flow once a quarter or so, to see whether it bears any relationship to the net income in the headlines. That's what we do with this series. Today, we're checking in on Tidewater (NYSE: TDW  ) , whose recent revenue and earnings are plotted below.

  • [By Garrett Cook]

    Energy shares fell around 0.95 percent in Monday’s trading. Top losers in the sector included Goodrich Petroleum (NYSE: GDP), down 8.39 percent, and Tidewater (NYSE: TDW), off 4.81 percent.

Hot Cheapest Companies To Invest In 2015: China Automotive Systems Inc.(CAAS)

China Automotive Systems, Inc., through its interests in Sino-foreign joint ventures, engages in the manufacture and sale of power steering systems and other component parts for the automotive industry in the People?s Republic of China. It offers a range of steering system parts for passenger automobiles and commercial vehicles. The company provides 4 separate series, 307 models of power steering, including rack and pinion power steering, integral power steering, electronic power steering and manual steering, steering columns, steering oil pumps, and steering hoses. China Automotive Systems, Inc. was founded in 2003 and is headquartered in Jing Zhou City, the People?s Republic of China.

Advisors' Opinion:
  • [By Richard Schmidt]

    China Automotive Systems (CAAS), which makes auto systems and components, reported record-high net sales for the third quarter. The report excited investors, who bid the stock up about 30% for the month.

  • [By Richard Schmidt]

    We admittedly bought into China Automotive Systems (CAAS) too soon. The stock is still down from our original recommendation price, but the future looks very bright.

Hot Cheapest Companies To Invest In 2015: Sumitomo Mitsui Financial Group Inc(SMFG)

Sumitomo Mitsui Financial Group, Inc., through its subsidiaries, provides various banking and financial products and services in Japan, the Americas, Europe, the Middle East, Asia, and Oceania. It operates in four segments: Commercial Banking, Securities, Leasing, and Credit Card. The commercial banking segment offers various financial services, including personal bank accounts, investment trusts, pension-type insurance products, life insurance products, and housing loans to individuals; and lending, cash management, settlement, leasing, factoring, management information systems consulting, collection, and investment banking services to mid-sized companies, and small- and medium-sized enterprises. It also provides various financial services, such as loans, deposits, and settlement services, as well as loan syndication, structured finance, and nonrecourse loans to large corporations and listed companies; international banking services comprising project finance, loan syndic ation, securitization, shipping finance, global cash management services, and yen custody services; and provides services related to foreign exchange, securities, and derivatives. The Securities segment offers various financial products, including stocks, bonds, investment trusts, and variable annuity insurance; investment consultation; and administration services to individual and corporate customers. The Leasing segment offers provides leasing services, such as leasing of information and communication equipment, industrial equipment, and construction equipment, as well as aircraft leasing. The Credit Card segment provides various credit cards; and settlement and financing services primarily related to credit card transactions. Sumitomo Mitsui Financial Group, Inc. is headquartered in Tokyo, Japan.

Advisors' Opinion:
  • [By MARKETWATCH]

    LOS ANGELES (MarketWatch) - Japanese stocks slipped at the open of trade Tuesday, as the Nikkei Stock Average pulled back from its 2.3% rally in the previous session. The Nikkei Stock Average (JP:NIK) shed 22 points, or 0.1%, to 15,628.07, and the broader Topix was flat at 1,255.14. Financial shares as well as some tech names were under pressure, including Trend Micro Inc. (JP:4704) (TMICY) , shares of which fell 2.8% following their 3% surge on Monday, and Sumitomo Mitsui Financial Group Inc. (JP:8316) (SMFG) as its stock lost 0.8%. In the currency market, the U.S. dollar held above the 楼103 level and the euro moved up toward 楼142.

  • [By MARKETWATCH]

    LOS ANGELES (MarketWatch) -- Japanese stocks opened higher Tuesday, with shares of exporters supported by further weakness in the yen against the U.S. dollar. The Nikkei Stock Average (JP:NIK) rose 62 points, or 0.4%, to 15,716.60, and the broader Topix gained 0.2%. The dollar on Monday bought more than 楼103 for the first time since May, bolstered by better-than-expected U.S. manufacturing data. Shares of Mazda Motor Corp. (JP:7261) (MZDAF) paced advancers in the auto sector, with their climb of 2.1% adding to Monday's rise of 2.3%. Among tech names, Fujifilm Holdings Corp. (JP:4901) (FUJIF) picked up 1.9%, TDK Corp. (JP:6762) (TTDKF) rose 1.2%. Financial issues, however, were mostly lower, with Sumitomo Mitsui Financial Group Inc. (JP:8316) (SMFG) off 0.2%.

Hot Cheapest Companies To Invest In 2015: Energizer Holdings Inc (ENR)

Energizer Holdings, Inc. (Energizer), incorporated on September 23, 1999, is the manufacturer and marketer of primary batteries, portable lighting and personal care products in the wet shave, skin care, feminine care and infant care categories. The Company manufactures and sells products in five product categories: wet shave, skin care, feminine care, infant care, battery and portable lighting products. On October 23, 2013, it completed the acquisition of the Stayfree pad, Carefree liner and o.b. tampon feminine hygiene brands in the United States, Canada and the Caribbean from McNeil PPC, Inc. and Johnson & Johnson, Inc., members of the Johnson & Johnson Family of Consumer Companies.

Personal Care

The Personal Care division includes wet shave products sold under the Schick, Wilkinson Sword, Edge, Skintimate and Personna brand names, skin care products sold under the Banana Boat, Hawaiian Tropic, Wet Ones and Playtex brand names, and feminine care and infant care products sold under the Playtex and Diaper Genie brand names globally. The Company manufactures and distributes Schick and Wilkinson Sword razor systems, composed of razor handles and refillable blades, and disposable shave products for men and women. The Company markets its wet shave products globally. The Company also manufactures, distributes and sells a complete line of private label and value-priced wet shaving disposable razors, shaving systems and replacement blades. These wet shave products are sold primarily under a retailer's store name or under value brand names such as Personna and GEM.

Household Products

Energizer's Household Products division manufactures and markets product portfolios in household batteries, specialty batteries and lighting products. In household batteries, the Company offers batteries using carbon zinc, alkaline, rechargeable and lithium technologies. The Company distributes its portfolio of household and specialty batteries and portable lighting products th! rough a global distribution network, which also provides a platform for the distribution of its personal care products.

The Company competes with Duracell International, Inc., Panasonic Corporation, Procter & Gamble Company, Bic Group, Kimberly-Clark Corp., Merck & Co., Inc. and Johnson & Johnson.

Advisors' Opinion:
  • [By Johanna Bennett]

    Energizer Holdings (ENR) shed 5.9% to $96.15. The company on Wednesday said its fiscal first-quarter profit slumped to $1.71 a share from $129.8 million in the year-earlier period. Excluding charges, earnings fell to $2.10 a share from $2.20 a share. The company best known for batteries also cut its full-year profit target to $7 a share to $7.25 a share, The Wall Street Journal said.

Hot Cheapest Companies To Invest In 2015: Southern Cross Exploration NL (SXX)

Southern Cross Exploration NL is an Australia-based company engaged in the investment in the Bigrlyi Uranium Joint Venture, on which pre-development investigations and further drilling were carried out; exploration for gold and minerals, reviews of opportunities for participation in and/or acquisition of mineral exploration and mining ventures, and examination of projects in respect of different commodities, share investments, loans and other securities. The Bigrlyi project is located in the Ngalia Basin, northwest of Alice Springs, in the Northern Territory. The Company's interest in the Bigrlyi Uranium Joint Venture is one of its assets, in joint venture with two multi-billion dollar companies, CGNPC - via the Operator, Energy Metals Ltd (EME) - and Paladin Energy Ltd (PDN). Advisors' Opinion:
  • [By idahansen]

    Due to the impact of The Great Recession, stocks in the agricultural sector such as Caterpillar (NYSE: CAT), The Mosiac Company (NYSE: MOS), and Potash of Saskatchewan (NYSE: POT) are trading well below highs. The exchange traded fund for the industry, DBA Power Shares, (NYSE: DBA), is down more than 17% for the last year. Despite this bearish trend, legendary investors such as Warren Buffett, George Soros, and Jim Rogers are very positive for the agriculture group. With the long term bullish outlook for the sector from the greatest investors in history, small cap stocks active in the fertilizer sector such as Sirius Minerals (LSE: SXX) and Americas Petrogas (TSX: BOE) are especially attractive.

Hot Cheapest Companies To Invest In 2015: Freeport-McMoran Copper & Gold Inc.(FCX)

Freeport-McMoRan Copper & Gold Inc. engages in the exploration, mining, and production of mineral resources. The company primarily explores for copper, gold, molybdenum, silver, and cobalt. It holds interests in various properties, located in North and South America; the Grasberg minerals district in Indonesia; and the Tenke Fungurume minerals district in the Democratic Republic of Congo. As of December 31, 2010, the company?s consolidated recoverable proven and probable reserves totaled 120.5 billion pounds of copper, 35.5 million ounces of gold, 3.39 billion pounds of molybdenum, 325.0 million ounces of silver, and 0.75 billion pounds of cobalt. The company was founded in 1987 and is headquartered in Phoenix, Arizona.

Advisors' Opinion:
  • [By Lu Wang]

    Mining stocks are bargains after declines in the past two years, said Hodges, who recently bought shares of Freeport-McMoRan (FCX) and U.S. Steel Corp. The selloff since the start of 2011 has erased almost half of the market value from a gauge of seven S&P 500 metal producers, data compiled by Bloomberg show. The price-earnings ratio for Phoenix-based Freeport, the world�� largest publicly traded copper producer, has dropped 24 percent since the beginning of 2010 to 11.5.

  • [By Lee Jackson]

    Freeport-McMoran Copper & Gold Inc. (NYSE: FCX) has been battered as investors have fled mining companies. The company is planning to enter the U.S. oil and gas space, which could truly make it a powerhouse. The company reported strong third-quarter earnings that beat Wall Street expectations convincingly. Fourth-quarter earnings were solid, but sales numbers were slightly lower than expected. Investors are paid a solid 3.5% dividend.�Jefferies has a $45 price target for the stock, and the consensus is posted at $39.85. The stock closed Thursday at $33.68.

  • [By Douglas A. McIntyre]

    In some cases, management decisions may not have had shareholders��best interests at heart. Freeport-McMoRan�� (NYSE: FCX) acquisition of two oil producers in 2012 immediately raised questions of self-dealing and led to a shareholder lawsuit. The lawsuit alleged that, with six board members holding seats on one of the companies involved, Freeport directors were effectively using company funds to bail out their own investment.

Hot Cheapest Companies To Invest In 2015: Constellium NV (CSTM)

Constellium N.V., formerly Constellium Holdco BV, is a Netherlands-based company, which is engaged in the manufacture of aluminum products and solutions. The Company is a supplier of such sectors as: aerospace, automotive and packaging. Constellium Holdco BV offers plates, sheet and coil, precision casting, cockpit carriers for vehicles, vehicle safety components, profiles, as well as tubes and bars, among others. Its main customers include: Airbus, Boeing, Embraer, Audi, BMW, Citroen, Renault, Mercedes Benz, Jaguar and others. The Company is active domestically and abroad, including North America, Europe and Asia. Advisors' Opinion:
  • [By GuruFocus]

    George Soros (Trades, Portfolio) just reported his first quarter portfolio. He buys Citrix Systems Inc, Baker Hughes Inc, Comcast Corp, Spansion Inc, etc during the 3-months ended 03/31/2014, according to the most recent filings of his investment company, Soros Fund Management LLC. As of 03/31/2014, Soros Fund Management LLC owns 305 stocks with a total value of $10.1 billion. These are the details of the buys and sells.New Purchases: BHI, CODE, CTRP, CLI, AVB, COMM, CNQ, AGO, AUY, ATML, ASH, BXMT, CSTM, AEM, CMA, ARE, CHKP, AUQ, BEAV, CX, ADSK, AALCP, BLK, AIG, BIIB, ADEP, AMRI, ARWR, ATHX, BALT, BCRX, BEAT, CFX, CLFD, CUR, CODE,Added Positions: CTXS, CMCSA, CNP, ALTR, BRCD, CBS, CRM, CHTR, CCJ, CIEN, BIDU, ALLE, ABT, CDNS, ACT,Reduced Positions: AAPL, CCI, AMT, ABBV, AAL, BITA, AL, ANGI, ARIA, CBST, BA, BIRT, EXAR,Sold Out: C, BAC, CRI, AMZN, AGN, CF, BRCM, COTY, BMY, AMCX, CAR, A, ADBE, AFL,For the details of George Soros (Trades, Portfolio)'s stock buys and sells, go to http://www.gurufocus.com/StockBuy.php?GuruName=George+SorosThis is the sector weightings of his portfolio:Technology18.9%Energy14%Healthcare8.3%Consumer Defensive8.2%Communication Services8.1%Consumer Cyclical5.4%Industrials5.1%Basic Materials4.9%Financial Services2.5%Real Estate1.9%Utilities0.5%These are the top 5 holdings of George Soros (Trades, Portfolio)1. Teva Pharmaceutical Industries Ltd (TEVA) - 10,310,041 shares, 5.4% of the total portfolio. Shares added by 10.67%2. Herbalife Ltd (HLF) - 4,901,337 shares, 2.8% of the total portfolio. Shares added by 52.9%3. EQT Corp (EQT) - 2,573,814 shares, 2.5% of the total portfolio. Shares added by 3.27%4. Adecoagro SA (AGRO) - 25,915,076 shares, 2.1% of the total portfolio.5. Halliburton Co (HAL) - 3,596,353 shares, 2.1% of the total portfolio. Shares reduced by 20.73%New Purchase: Baker Hughes Inc (BHI)George Soros (Trades, Portfolio) initiated holdings in Baker Hughes Inc. His purchase prices were between $51.82 and $65.27, with an estimated

  • [By Jan-e- Alam]

    Constellium (NYSE: CSTM  ) is a downstream aluminum producer engaged in the design, manufacture, and sale of specialty rolled and extruded aluminum products. The Netherlands-based company, which offers its products primarily to the aerospace, automotive, and packaging industries, is a world leader in the manufacturing of high-quality aluminum products and solutions.

Wednesday, June 17, 2015

PartnerRe Dipped to Neutral - Analyst Blog

Top 10 Industrial Conglomerate Stocks To Invest In 2016

On Jul 11, we downgraded global life and property-casualty (P&C) insurer and reinsurer – PartnerRe Ltd. (PRE) – to Neutral based on its weak investment portfolio and high competition. While the Presidio acquisition diversifies the company's product profile, it brings in additional costs that will weigh on margins at least for some time.

Why the Downgrade?

Estimates for PartnerRe witnessed modest corrections after the company reported its first-quarter 2013 results on Apr 29, wherein earnings stood at $3.39 per share. Earnings per share outpaced both the Zacks Consensus Estimate and year-ago number of $2.47 and $2.76, respectively. Overall, PartnerRe delivered positive earnings surprises in all of the last 4 quarters with an average beat of 151.1%.

However, total revenue edged down 2.6% year over year to $1.3 billion and was almost in line with the Zacks Consensus Estimate. Growth from premiums written was more than offset by lower investment income.

While total expenses surged 13%, combined ratio improved to 81.7% from 84.7% in the year-ago period. In addition, technical results and underwriting profitability improved, driving growth in bottom line, book value per share and return on equity (ROE).

Following the release of the first-quarter results, the Zacks Consensus Estimate for 2013 inched up 1.8% to $9.25 per share in the last 60 days. Moreover, the Zacks Consensus Estimate for 2014 edged up about 1.0% to $8.11 per share in the last 60 days.

With the Zacks Consensus Estimates for both 2013 and 2014 exhibiting no clear directional pressure in the near term and estimates for both the years posing year-over-year deterioration, PartnerRe now has a Zacks Rank #3 (Hold).

Cause for Concern

The recent acquisition of Presidio not only drove the premiums of PartnerRe but ! also helped the company diversify. Presidio's robust market presence and expert management should further strengthen the company's fundamentals. However, concerns linger over the sustainability of this growth amid the weak P&C market and a history of challenges faced in the integration of ParisRe.

Moreover, intense competition, currency fluctuations, weak credit spreads and low interest rate environment have restricted investment income and yields, thereby limiting the desired upsides. Nevertheless, PartnerRe enjoys above-average liquidity and a low-risk balance sheet, which is reflected in its consistent and efficient capital deployment. In the long run, a stable ratings outlook, improved pricing and market stability can help mitigate the cyclical declines.

Other Insurers That Warrant a Look

While we prefer to avoid PartnerRe until we gain more clarity on the stock's performance, other P&C insurers and reinsurers that are worth a look are AmTrust Financial Services Inc. (AFSI), HCI Group Inc. (HCI) and American Safety Insurance Holdings Inc. (ASI). All these stocks carry a Zacks Rank #1 (Strong Buy).